Topical capsaicin for cannabinoid hyperemesis syndrome reduced medication use and opioid requirements in the ER
Topical capsaicin applied to patients with cannabinoid hyperemesis syndrome in the emergency department did not significantly shorten visits but reduced the number of additional medications needed and lowered opioid use.
Quick Facts
What This Study Found
ED length of stay was reduced by a median of 22 minutes with capsaicin but this was not statistically significant. Capsaicin-treated patients received fewer additional medication doses (3 vs. 4, p=0.015), and 67% required no further treatment. Opioid use was lower in the capsaicin group (69 vs. 166.5 mg oral morphine equivalents). 42% had no repeat ED visit for CHS in the following 3 months.
Key Numbers
43 patients. ED LOS: 179 vs. 201 minutes (not significant, p=0.33). Fewer additional medications: 3 vs. 4 doses (p=0.015). 67% needed no further treatment after capsaicin. Opioid use: 69 vs. 166.5 mg OME. Cost difference: $3.26 more for capsaicin. No significant adverse events.
How They Did This
Retrospective cohort analysis of 43 patients presenting with CHS. Compared ED visits where capsaicin was used versus visits without capsaicin. Outcomes included ED length of stay, rescue medication use, opioid requirements, costs, and adverse events.
Why This Research Matters
CHS is notoriously difficult to treat with standard antiemetics. Topical capsaicin is inexpensive, available over-the-counter, and could reduce opioid use in a population that frequently presents to emergency departments.
The Bigger Picture
An inexpensive OTC treatment that reduces opioid use and additional medications in the ER could change CHS management. The potential for at-home self-treatment with capsaicin cream could also reduce unnecessary ED visits.
What This Study Doesn't Tell Us
Retrospective design with a small sample. No randomization or blinding. Some patients served as their own controls across visits, but confounders were not fully controlled. The p-value for the primary outcome (LOS) was not significant.
Questions This Raises
- ?Would a randomized controlled trial confirm capsaicin's benefits for CHS?
- ?Could at-home capsaicin use prevent ED visits?
- ?What is the optimal capsaicin concentration and application site?
Trust & Context
- Key Stat:
- 67% of capsaicin-treated CHS patients needed no further medication
- Evidence Grade:
- Retrospective cohort with a small sample and no randomization. Suggestive findings that need confirmation in controlled trials.
- Study Age:
- 2020 retrospective study. Adds to growing case evidence for topical capsaicin in CHS management.
- Original Title:
- Efficacy and safety of topical capsaicin for cannabinoid hyperemesis syndrome in the emergency department.
- Published In:
- Clinical toxicology (Philadelphia, Pa.), 58(6), 471-475 (2020)
- Database ID:
- RTHC-02901
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
How does capsaicin help with CHS?
Capsaicin activates TRPV1 receptors, the same receptors involved in the body's temperature regulation system that is disrupted in CHS. This activation may counteract the mechanism causing symptoms.
Can capsaicin be used at home for CHS?
The study authors suggest that capsaicin's availability as an over-the-counter product could empower at-home treatment, potentially reducing unnecessary emergency department visits.
Read More on RethinkTHC
- 420-sober-survival-guide
- CBT-cannabis-recovery
- THC-potency-increase-over-time
- cannabis-harm-reduction-opioids-alcohol-replacement
- cannabis-legalization-effects-health-data
- cannabis-relapse-cycle-pattern
- cannabis-tolerance-break-guide
- cold-turkey-vs-taper-quit-weed
- dating-sober-after-quitting-weed
- exercise-quitting-weed-anxiety-brain
- grieving-quitting-weed-loss
- help-someone-quit-weed
- how-to-cut-back-on-weed-moderation
- how-to-quit-weed
- journaling-weed-withdrawal
- marijuana-anonymous-SMART-recovery-compare
- meditation-mindfulness-weed-withdrawal
- microdosing-cannabis-benefits
- partner-still-smokes-weed
- partner-still-smokes-weed-quitting
- pink-cloud-sobriety-cannabis
- quit-weed-cold-turkey
- quit-weed-or-cut-back-which-is-better
- quit-weed-regret-went-back
- quitting-weed-20s
- quitting-weed-30s
- quitting-weed-after-years
- quitting-weed-during-crisis-divorce-job-loss
- quitting-weed-exercise
- quitting-weed-grief-loss-coping
- quitting-weed-legal-state
- quitting-weed-success-stories
- quitting-weed-triggers-environment
- relapsed-smoking-weed-what-to-do
- relapsed-weed
- safer-cannabis-use-guidelines
- should-i-quit-weed
- sober-music-festival-concert-without-weed
- sober-october-weed
- supplements-weed-withdrawal
- telling-friends-quitting-weed
- tolerance-break-weed
- weed-for-opioid-withdrawal
- weed-relapse-prevention-plan
- weed-relapse-why-it-happens
- weed-ritual-replacement
- weed-ruined-relationships
- weed-social-media-triggers-quit
Cite This Study
https://rethinkthc.com/research/RTHC-02901APA
Wagner, Samantha; Hoppe, Jason; Zuckerman, Matthew; Schwarz, Kerry; McLaughlin, Julie. (2020). Efficacy and safety of topical capsaicin for cannabinoid hyperemesis syndrome in the emergency department.. Clinical toxicology (Philadelphia, Pa.), 58(6), 471-475. https://doi.org/10.1080/15563650.2019.1660783
MLA
Wagner, Samantha, et al. "Efficacy and safety of topical capsaicin for cannabinoid hyperemesis syndrome in the emergency department.." Clinical toxicology (Philadelphia, 2020. https://doi.org/10.1080/15563650.2019.1660783
RethinkTHC
RethinkTHC Research Database. "Efficacy and safety of topical capsaicin for cannabinoid hyp..." RTHC-02901. Retrieved from https://rethinkthc.com/research/wagner-2020-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.